19 citations
,
April 2024 in “International Journal of Environmental Research and Public Health” Long COVID symptoms are linked to immune issues, poor blood flow, and lung problems.
15 citations
,
January 2014 in “Dermatology” Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
4 citations
,
October 2023 in “Journal of clinical medicine” Women with PCOS are much more likely to experience depression.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
March 2019 in “European archives of medical research” Platelet-rich plasma injections are a cheap and effective way to reduce hair loss and improve hair quality in people with mild to moderate androgenetic alopecia.
3 citations
,
February 2023 in “International Journal of Molecular Sciences” Autologous Platelet and Extracellular Vesicle-Rich Plasma (PVRP) has potential in enhancing tissue regeneration and improving hair conditions, but its effectiveness varies due to individual differences.
2 citations
,
September 2023 in “Cosmetics” Cannabinoids may help some skin conditions but more research is needed.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
April 2024 in “Indian Journal of Paediatric Dermatology” Children with alopecia areata in Singapore generally have a good quality of life.
December 2024 in “Value in Health” A comprehensive approach is needed to accurately assess alopecia areata severity and guide treatment decisions.
63 citations
,
March 2020 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
16 citations
,
December 2008 in “Journal of The American Academy of Dermatology” Adults with atopic dermatitis showed similar adherence to different forms of hydrocortisone cream, but actual use varied despite self-reports of near-perfect usage.
January 2025 in “Journal of Plastic Reconstructive & Aesthetic Surgery” Two L-PRP treatments improve hair density in mild to moderate alopecia.
May 2024 in “Journal of the Egyptian Womenʼs Dermatologic Society” Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
4 citations
,
November 2022 in “Frontiers in Medicine” People with alopecia areata are more likely to have anxiety and depression and a lower quality of life.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
January 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Both cryotherapy and FCO2 laser are effective and safe for treating patchy alopecia areata.
17 citations
,
June 2024 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly affects mental health, especially in women and those with severe cases.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
3 citations
,
March 2023 in “JAAD case reports” Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
April 2023 in “Journal of Investigative Dermatology” Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.
The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Hair loss from alopecia areata and androgenetic alopecia moderately affects the quality of life, especially in younger patients and those with long-term hair loss, impacting both their physical and emotional well-being.
1 citations
,
June 2025 in “Frontiers in Immunology” Higher IgE levels may play a role in alopecia areata, especially in males, children, and severe cases.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.